Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | PREP | P48147 | 4/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15793987 | 0.86 | CA12 (0.45) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL20535821 | 0.82 | CA12 (0.39) | CA12CA1CA9PREP | |
| SCHEMBL4651443 | 0.81 | CA12 (0.46) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL17836741 | 0.81 | CA12 (0.46) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL24455832 | 0.79 | CA12 (0.45) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL29653234 | 0.79 | CA12 (0.45) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL29722959 | 0.79 | CA12 (0.45) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL27083608 | 0.79 | CA12 (0.46) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL14992681 | 0.77 | CA12 (0.46) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL7045640 | 0.77 | CA12 (0.46) | CA12CA1CA9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-08-08 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| CN-110678450-B | Isoxazole derivatives as nuclear receptor agonists and uses thereof | 日东制药株式会社 | 2023-06-20 | — | — | CN | disclosed |
| WO-2023090858-A1 | METHOD FOR PREPARING ISOXAZOLE DERIVATIVE, AND INTERMEDIATE THEREOF | 일동제약(주) | 2023-05-25 | — | — | WO | disclosed |
| EP-3612520-B1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMA (KR) | 2021-11-10 | — | — | EP | disclosed |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2021-06-24 | — | — | US | disclosed |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2021-06-24 | — | — | US | disclosed |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-27 | — | — | US | disclosed |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-27 | — | — | US | disclosed |
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2020-04-16 | — | — | US | disclosed |
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2020-04-16 | — | — | US | disclosed |
| EP-3612520-A1 | AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF | Il Dong Pharmaceutical Co., Ltd. (KR) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018190643-A1 | AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | CA12 4239/4885CA1 3187/4885CA9 3834/4885 |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | CA12 4458/4885CA1 4348/4885CA9 3671/4885 |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | CA12 4239/4885CA1 3187/4885CA9 3834/4885 |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | CA12 4547/4885CA1 4318/4885CA9 3778/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | CA12 4458/4885CA1 4348/4885CA9 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.